Global, Regional, and National Burden of Early-Onset Alzheimer's Disease and Other Dementias in Young Adults Aged 40–64 Years, 1990–2021: A Population-Based Study

IF 4.5 2区医学 Q1 CLINICAL NEUROLOGY European Journal of Neurology Pub Date : 2025-03-19 DOI:10.1111/ene.70116

Zenghui Zhang, Shaojie Han, Huimin Zhu, Qianyun Wang, Siyuan Cheng, Yuchen Han, Fengjuan Li, Jun Guo

{"title":"Global, Regional, and National Burden of Early-Onset Alzheimer's Disease and Other Dementias in Young Adults Aged 40–64 Years, 1990–2021: A Population-Based Study","authors":"Zenghui Zhang, Shaojie Han, Huimin Zhu, Qianyun Wang, Siyuan Cheng, Yuchen Han, Fengjuan Li, Jun Guo","doi":"10.1111/ene.70116","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Purpose</h3>\n \n <p>Early-onset Alzheimer's disease and other dementias (EOAD) impose significant burdens on affected individuals and their families. However, the global burden of EOAD has not been fully investigated. We aimed to assess the global, regional, and national burden of EOAD using data from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) study from 1990 to 2021.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data for adults aged 40–64 were extracted within the GBD 2021 framework. Primary outcomes included age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) for EOAD, as well as average annual percentage change (AAPC) across 21 regions and 204 countries.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 2021, EOAD cases reached 7.75 million (95% uncertainty interval [UI] 5.82–10.08), up from 3.67 million cases (95% UI 2.75–4.76) in 1990. The age-standardized prevalence rate increased from 341.2 per 100,000 (95% UI 255.89–442.79) in 1990 to 363.5 per 100,000 in 2021, with an AAPC of 0.26% (<i>p</i> < 0.001). EOAD prevalence was higher in women than in men in 2021 (4.28 million, 95% UI 3.24–5.56, vs. 3.46 million, 95% UI 2.57–4.52). EOAD was associated with 0.07 million (95% UI 0.01–0.23) deaths and 3.77 million (95% UI 1.69–8.88) DALYs in 2021. Additionally, 1.06 million (95% UI 0.07–3.03) DALYs were attributable to smoking, elevated fasting plasma glucose, and high body mass index.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The global number of EOAD cases among adults aged 40–64 years more than doubled from 1990 to 2021. Targeted strategies and interventions are urgently needed to address this growing public health issue.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"32 3","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.70116","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.70116","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Purpose

Early-onset Alzheimer's disease and other dementias (EOAD) impose significant burdens on affected individuals and their families. However, the global burden of EOAD has not been fully investigated. We aimed to assess the global, regional, and national burden of EOAD using data from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) study from 1990 to 2021.

Methods

Data for adults aged 40–64 were extracted within the GBD 2021 framework. Primary outcomes included age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) for EOAD, as well as average annual percentage change (AAPC) across 21 regions and 204 countries.

Results

In 2021, EOAD cases reached 7.75 million (95% uncertainty interval [UI] 5.82–10.08), up from 3.67 million cases (95% UI 2.75–4.76) in 1990. The age-standardized prevalence rate increased from 341.2 per 100,000 (95% UI 255.89–442.79) in 1990 to 363.5 per 100,000 in 2021, with an AAPC of 0.26% (p < 0.001). EOAD prevalence was higher in women than in men in 2021 (4.28 million, 95% UI 3.24–5.56, vs. 3.46 million, 95% UI 2.57–4.52). EOAD was associated with 0.07 million (95% UI 0.01–0.23) deaths and 3.77 million (95% UI 1.69–8.88) DALYs in 2021. Additionally, 1.06 million (95% UI 0.07–3.03) DALYs were attributable to smoking, elevated fasting plasma glucose, and high body mass index.

Conclusions

The global number of EOAD cases among adults aged 40–64 years more than doubled from 1990 to 2021. Targeted strategies and interventions are urgently needed to address this growing public health issue.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

European Journal of Neurology 医学-临床神经学

CiteScore

9.70

自引率

2.00%

发文量

418

审稿时长

1 months

期刊介绍： The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).